 |
|
|
|||||
This morning, the worlds largest telescope revealed its first-ever images of spaceand theyre pretty jaw-dropping. The images come courtesy of the NSFDOE Vera C. Rubin Observatory, a scientific facility funded by the U.S. National Science Foundation and the U.S. Department of Energy’s Office of Science. Located at the summit of Cerro Pachón in Chile, the facility is the product of more than 20 years of work. Its space cameraembedded in the hulking Large Synoptic Survey Telescope (LSST)is about the size of a small car and includes a sensor array of 3 billion pixels, the most sensors ever used in a telescope camera. According to a press release from the Rubin Observatory, its expected to generate an ultrawide, ultra-high-definition time-lapse record of the universe. It will bring the sky to life with a treasure trove of billions of scientific discoveries, the release reads. The images will reveal asteroids and comets, pulsating stars, supernova explosions, far-off galaxies, and perhaps cosmic phenomena that no one has seen before. The most efficient Solar System discovery machine ever built In just its first 10-hour test observation, unveiled today, the LSST managed to capture images that include millions of galaxies and Milky Way stars, as well as more than 2,000 never-before-seen asteroids within our solar system. Taken together, the photos illustrate a technicolor view of space at a mind-boggling scalebut the 10 million galaxies photographed by the LSST represent only 0.05% of the roughly 20 billion galaxies that the camera is expected to record within the next decade. The primary goal of the LSST is to complete a 10-year survey of the Southern Hemisphere sky, capturing hundreds of images and around 20 terabytes of data per night throughout that period. Per the Rubin Observatory, this massive influx of data will make the LSST the most efficient and effective solar system discovery machine ever built. All of the captured data will be made available online, allowing astronomers across the globe to access countless new findings without physical access to the telescope. The LSST is designed to advance four main areas of study: understanding the nature of dark matter and dark energy; creating an inventory of the solar system; mapping the Milky Way; and exploring the transient optical sky (studying objects that move or change in brightness). Experts predict that, given its capacity to identify millions of unseen asteroids, comets, and interstellar objects, the camera could even help protect the planet by spotting objects on a trajectory toward the Earth or moon. NSFDOE Rubin Observatory will capture more information about our universe than all optical telescopes throughout history combined, Brian Stone, chief of staff at the National Science Foundation, said in a press release. Through this remarkable scientific facility, we will explore many cosmic mysteries, including the dark matter and dark energy that permeate the universe.
Category:
E-Commerce
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns over Hims & Hers knock-off weight loss drugs. Now, Hims & Hers shares are plummeting as investors react to the news. Its the latest update in a somewhat volatile year for Hims & Hers. Just this April, the companys stock spiked after it initially announced a collaboration with Novo Nordisk that allowed Hims & Hers to sell Novo Nordisks FDA-approved weight loss drug, Wegovy, through its platform. But less than two months later, that partnership is fracturing after Novo Nordisks claim that Hims & Hers engaged in deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk. At the time of this writing, HIMS stock is down 32.6% since market open. Heres what to know about the break-up: The shortage that fueled knock-off Wegovy Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand name drugs using their active ingredient, semaglutide, and sell them at a lower cost. Hims & Hers was one company that took part in selling a compoundedand non-FDA-approvedversion of Wegovy. Then, this February, the FDA announced that Ozempic and Wegovy were no longer categorized under a shortage. With the brand name drugs fully back on the market, the FDA gave compounders 60 to 90 days to stop making copies of the patented drugs. At the time, Hims & Hers stated in a regulatory filing that, while it saw pathways to continue offering access to certain compounded GLP-1s after the shortage, it could not “guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all.” However, an analyst told Reuters that Hims & Hers appeared poised to continue selling compounded semaglutide using personalized doses after the shortage officially ended. Why is Novo Nordisk cutting ties now? In the wake of the FDAs shortage notice, Hims & Hers announced in April that it was entering a long-term collaboration with Novo Nordisk to offer Wegovy directly to its consumers. Now, though, Novo Nordisk is breaking off the commitment over claims that Hims & Hers has not acted fast enough to stop selling its compounded GLP-1. Other telehealth companies, like Ro and Noom, have similarly faced criticism for continuing to sell their own compounded GLP-1 despite agreements with Eli Lilly, the maker of Zepbound. In an email to Fast Company, a Novo Nordisk spokesperson explained that semaglutide compounding is permitted under US compounding laws only in rare instances, adding that other companies its working with have demonstrated a good faith effort to transition patients to authentic, FDA-approved Wegovy. However, the spokesperson continued, after over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of personalization and are disseminating deceptive marketing that puts patient safety at risk. This is unacceptable and that is why we have decided to end the collaboration. That personalization, involves offering the same drug; however, at different doses. In a press release published this morning, Novo Nordisk also noted that it is deeply concerned about knock-off drugs made with foreign illicit active pharmaceutical ingredients. Based on Novo Nordisk’s investigation, the semaglutide active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China, the release reads. According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the semaglutide they produce. Hims & Hers did not immediately respond to Fast Companys request for comment on Novo Nordisks claims. On X, Novo Nordisk CEO Andrew Dudam said “Novo Nordisks commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical companys anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.” He went on to say “We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.” We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisks commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to— andrewdudum (@AndrewDudum) June 23, 2025
Category:
E-Commerce
Two of the nation’s real estate titans are on a collision course. Compass, one of the largest brokerages in the country, has filed a complaint in a New York federal court against Zillow, alleging the online behemoth is engaging in “anticompetitive tactics” and violating antitrust laws. The suit accuses Zillow of banning listings that were marketed elsewhere first, saying it has “retaliated against competitive threats by enacting an exclusionary policy.” This lawsuit is about protecting consumer choice, said Robert Reffkin, Compass founder and CEO, in a statement to Fast Company. No one company should have the power to ban agents or listings simply because they dont follow that companys business model. Consumers should have the right to choose how they sell their homes. Zillow did not respond to Fast Company’s request for comment about the suit. The faceoff between the two companies has been brewing for some time. Compass has been growing steadily, most notably with last Decembers acquisition of Christies International Real Estate in a deal worth $444 million. Earlier this year, it was also reported to be in talks to buy the real estate brokerage business of Berkshire Hathaway. Compass has been promoting its Private Exclusives and Coming Soon online listings for several months, which feature thousands of homes available only to Compass agents and their buyers. Two months ago, Zillow unveiled a new policy that any home put on the market but not made available to Zillow within 24 hours would be banned from the site. “Instead of competing on the merits for home sellers, home buyers, and the agents who work for them, Zillow has sought to rely on anticompetitive tactics to protect its monopoly and revenues in violation of the antitrust laws,” the filing reads. The suit says Zillow has become the “vital, go-to destination for consumers looking to purchase homes,” through the “relentless acquisition of competitors” and “the power of network effects.” That, Compass claims, effectively makes it a tollbooth for agents, allegedly collecting up to 40% of the buyer agent commission for referring the buyer. Additionally, it accuses Zillow of charging potential buyers to tour listed propertiessomething that is typically free. “Every time a buyer requests a tour on Zillow, Zillow redirects the buyer away from the listing agent of the property, who would not charge the buyer an incremental commission,” the lawsuit states. “Instead, Zillow directs the buyer to a Zillow-affiliated buyer agent who charges the buyer an incremental commission to show the property.” Compass argues that it and other realtors should have the right to market homes themselves, without being required to send listings to Zillow. This sometimes involves an extended “coming soon” period, which Compass says allows sellers to showcase homes before they are fully market-ready, gauge early interest, and test demandwithout increasing the “days on market” count or triggering price reductions. Zillow, in April, argued that everyone should have access to that information, citing the National Association of Realtors’ long-standing clear cooperation policy, which requires agents to list homes on their local MLS within 24 hours of beginning any public marketing. “Listings shouldnt be used as leverage to control who gets to participate in the home-buying process,” Zillow wrote when announcing the new rules. “Practices that selectively share listings create confusion, harm consumers and erode trust in the marketplace. Its a bait-and-switch move, where agents or brokerages try to get the best of both worlds.” Compass, in its lawsuit, counters this argument, saying Zillow should not be allowed to ban listings that don’t align with its business model. “Zillow is so comfortable with its size and power that it has adopted a policy that governs what other real estate companies can do on platforms other than Zillow,” the complaint reads. “It effectively is leveraging its power to promulgate and enforce industry-wide rulemaking like a government regulator, despite being a private company that does not even provide brokerage services, represent home sellers and buyers, or create the listings on which it profits.”
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||